US 7,575,749 B2
	Serpentine transmembrane antigens expressed in human cancers and uses thereof
Daniel E. Afar, Pacific Palisades, Calif. (US); Rene S. Hubert, Los Angeles, Calif. (US); Kahan Leong, Playa Del Rey, Calif. (US); Arthur B. Raitano, Los Angeles, Calif. (US); Douglas Saffran, Encinitas, Calif. (US); and Steven Chappell Mitchell, Gurnee, Ill. (US)
Assigned to Agensys, Inc., Santa Monica, Calif. (US)
Filed on Jun. 01, 2004, as Appl. No. 10/858,887.
Application 10/858887 is a continuation of application No. 10/010667, filed on Dec. 06, 2001, granted, now 6,887,975, filed on May 03, 2005.
Application 10/010667 is a continuation of application No. 09/323873, filed on Jun. 01, 1999, granted, now 6,329,503, filed on Dec. 11, 2001.
Claims priority of provisional application 60/091183, filed on Jun. 30, 1998.
Claims priority of provisional application 60/087520, filed on Jun. 01, 1998.
Prior Publication US 2005/0202454 A1, Sep. 15, 2005
Int. Cl. A61K 39/38 (2006.01)

U.S. Cl. 424—184.1

3 Claims

1. A method for inducing a cellular immune response to the protein of SEQ ID NO:2 in a subject having a cancer expressing a protein comprising the amino acid sequence of SEQ ID NO:2, comprising administering to the subject a protein comprising the amino acid sequence of SEQ ID NO:2.